ARGININE POTENTIATES BUT DOES NOT RESTORE THE BLUNTED GROWTH-HORMONE RESPONSE TO GROWTH HORMONE-RELEASING HORMONE IN OBESITY

A blunted growth hormone (GH) response to several stimuli, including growth hormone-releasing hormone (GHRH), has been shown in obesity. Arginine (ARG) has been demonstrated to potentiate the GHRH-induced GH increase in normal subjects, likely acting via inhibition of hypothalamic somatostatin release. To shed further light onto the mechanisms underlying the blunted GH secretion in obesity, we studied the effect of ARG (0.5 g/kg infused intravenously [IV] over 30 minutes) on both basal and GHRH (1 μm/kg iv)-stimulated GH secretion. Eight obese subjects (aged 26.4 ± 3.9 years; body mass index, 39.0 ± 1.9 kg/m2) and eight normal control volunteers (aged 27.0 ± 1.7 years; body mass index, 22.3 ± 0.5 kg/m2) were studied. In obese subjects, the GH response to both GHRH and ARG was lower (P < .01 and P < .002, respectively) than in controls. ARG potentiated the GH response to GHRH in obese patients (P < .0003). However, in these patients, the GH secretion elicited by GHRH, even when coadministered with ARG, persisted at reduced levels (P < .005) when compared with controls. Basal insulin-like growth factor-1 (IGF-1) levels did not significantly differ in obese subjects and in normal subjects (161.1 ± 37.0 v 181.0 ± 12.8 μg/L). In conclusion, ARG enhances the blunted GHRH-induced GH increase in obese patients, but the GH responses to ARG alone and to ARG + GHRH persist at lower levels than in normals. Thus, our results suggest the existence of a reduced pituitary GH pool in obesity. © 1992.